Previous Close | 27.54 |
Open | 26.95 |
Bid | 28.05 x 1200 |
Ask | 30.50 x 800 |
Day's Range | 26.06 - 27.43 |
52 Week Range | 11.25 - 58.38 |
Volume | |
Avg. Volume | 1,401,705 |
Market Cap | 1.851B |
Beta (5Y Monthly) | -0.37 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.89 |
Earnings Date | May 13, 2024 - May 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 51.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for AKRO
Madrigal and other companies focused on treating fatty liver disease won’t get sidelined by obesity drugs.
Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.
Ionis (IONS) reports positive phase II study results, which show that treatment with ION224 has the potential to improve MASH and prevent its progression to more severe stages.